Navigation Links
HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
Date:5/29/2008

-Technology for quantitative profiling of protein biomarkers in tissue now available to investigators at DF/HCC member institutions through Brigham

and Women's Pathology Core Facility-

NEW HAVEN, Conn., May 29 /PRNewswire/ -- HistoRx, Inc., announced today that the pathology core facility at Brigham and Women's Hospital (BWH) will begin making the company's AQUA(R) technology for protein biomarker profiling available to the more than 900 Dana-Farber/Harvard Cancer Center (DF/HCC) scientists that are serviced by the facility. Brigham and Women's purchased a HistoRx PM-2000(TM) tissue analysis platform instrument, which incorporates the proprietary AQUA(R) technology, in 2005.

The pathology core facility at BWH is a service hub that provides state-of-the-art tissue-based tests and analysis to investigators at DF/HCC institutions, which include Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Children's Hospital Boston, Beth Israel Deaconess Hospital, and Massachusetts General Hospital. The core facility is using the AQUA(R) technology to identify and quantify protein biomarkers in tissue samples for researchers advancing studies on cancer diagnostics and drug development. Jon Aster, M.D., Ph.D., core facility director and Associate Professor in the Department of Pathology, and Scott Rodig, M.D., Ph.D., Assistant Professor in Pathology, both of BWH, will oversee the technology access expansion to the DF/HCC member institutions.

The PM-2000(TM) system, now in use at 12 leading cancer and pathology research centers through the HARP(TM) program (HistoRx Academic Research Program), enables the reliable measurement of protein biomarkers in tissue and tissue microarrays based on fluorescent immunohistochemical methods. Assays developed on the system may be used to better understand the origins of diseases as well as to aid in patient selection for clinical tri
'/>"/>

SOURCE HistoRx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
2. Favrille Announces Workforce Reduction
3. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
4. Genmab Announces 2008 First Quarter Results
5. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
6. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
7. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
8. WuXi PharmaTech Announces First Quarter 2008 Results
9. WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
10. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
11. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... Third Wave Technologies, Inc ., a manufacturer of molecular diagnostic ... Drug Administration for approval of a new Cystic Fibrosis ... calls InPlex, is a genotyping test to determine Cystic Fibrosis ... and in diagnostic testing in newborns and children. Cystic Fibrosis ...
... and lobbyists from AT&T and BellSouth must ... the band back together and no one can stop them. , ... off the largest telecom merger in U.S. history. I always ... company. They are another step closer to proving I was right ...
... a month ago, and already Microsoft's Windows Vista , the ... bruised by critical media reports about security flaws and other shortcomings. ... the beta version. We posed several questions to Justin Jaeck, vice ... information technologies for Veridian Homes , to get their take ...
Cached Biology Technology:AT&T - BellSouth merger: Revestiture continues 2AT&T - BellSouth merger: Revestiture continues 3AT&T - BellSouth merger: Revestiture continues 4AT&T - BellSouth merger: Revestiture continues 5AT&T - BellSouth merger: Revestiture continues 6Wisconsin firms won't rush to adopt Microsoft Vista 2Wisconsin firms won't rush to adopt Microsoft Vista 3Wisconsin firms won't rush to adopt Microsoft Vista 4
(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... Arlington, VA, March 18, 2010. How did China ... North America and Europe? A panel of U.S. experts ... comparative findings in a workshop at the National Science Foundation ... the sponsorship of the National Science Foundation and other Federal ...
... BOZEMAN, Mont. -- Bile secretions in the small ... to change their behavior to maximize their chances of ... the Society for General Microbiology during its spring meeting ... the findings could allow us to better protect food ...
... toxicologist and a multidisciplinary team of researchers have ... composed of 60 carbon atoms. The team also ... hold hope for treatment of Parkinson,s disease, Alzheimer,s ... appeared in Toxicology and Applied Pharmacology and represents ...
Cached Biology News:Workshop on R&D for rapid vaccine development and production in Asia/Australia 2Montana State researcher discovers that bile sends mixed signals to E. coli 2Carbon nanostructures -- elixir or poison? 2Carbon nanostructures -- elixir or poison? 3
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Ubiquitin Related I Sampler Kit 10 mu g each...
Chaperone Sampler Kit 10 mu g each...
Zonula Adherens Sampler Kit 10 mu g each...
Biology Products: